Use of a beta blocker for the manufacture of a medicament...

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 31/138 (2006.01) A61K 31/18 (2006.01) A61K 31/222 (2006.01) A61K 31/36 (2006.01) A61K 31/404 (2006.01) A61K 31/4045 (2006.01) A61K 31/4704 (2006.01) A61K 31/5377 (2006.01) A61P 17/00 (2006.01)

Patent

CA 2701953

The present invention relates the use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas, for example of infantile hemangiomas. The beta blocker may be a non-selective beta-blocker, for example propranolol. The present invention provides an alternative to the known compounds, e.g. corticosteroids, interferon or vincristine, generally used for the treatment of hemangiomas.

La présente invention concerne l'utilisation d'un bêta-bloquant pour la fabrication d'un médicament pour le traitement des hémangiomes, par exemple des hémangiomes infantiles. Le bêta-bloquant peut être un bêta-bloquant non sélectif, par exemple le propranolol. La présente invention fournit une alternative aux composés connus, p. ex. aux cordicostéroïdes, à l'interféron ou à la vincristine, généralement utilisés pour le traitement des hémangiomes.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Use of a beta blocker for the manufacture of a medicament... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of a beta blocker for the manufacture of a medicament..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of a beta blocker for the manufacture of a medicament... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1593769

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.